Operational volcanic ash monitoring during Etna volcanic crises

Operational systems able to monitor volcanic ash in real time and provide both critical eruption parameters and useful warnings to emergency responders and government agencies should be implemented in most volcanic observatories worldwide. Over the past ten years, more than fifty lava fountains occurred at Mt. Etna (Italy) that produced eruption columns more than 10 km a.s.l. and generated large tephra fallout around the volcano flanks. For civil protection purposes, there was the need to improve the already existing monitoring systems daily run at the Istituto Nazionale di Geofisica and Vulcanologia, mainly based on eruption scenarios (weak and strong plume scenarios). We present a new upgraded system that has multiple objectives: i) to have a fast system able to best identify the type of eruptive scenario; ii) to forecast the tephra deposit in near real time, i.e. within a few hours from the eruptive event; iii) to determine the area impacted by clasts larger than 5 cm that could severely injure hikers, guides, and volcanologists and damage infrastructures in proximity of Etna summit craters. This new system is based on the real-time estimate of column height from the analysis of images taken by SEVIRI satellite and by new calibrated cameras and using meteorological parameters obtained by local models.PublishedVienna , Austria6V. Pericolosità vulcanica e contributi alla stima del rischi

Near-Real-Time Tephra Fallout Assessment at Mt. Etna, Italy

During explosive eruptions, emergency responders and government agencies need to make fast decisions that should be based on an accurate forecast of tephra dispersal and assessment of the expected impact. Here, we propose a new operational tephra fallout monitoring and forecasting system based on quantitative volcanological observations and modelling. The new system runs at the Istituto Nazionale di Geofisica e Vulcanologia, Osservatorio Etneo (INGV-OE) and is able to provide a reliable hazard assessment to the National Department of Civil Protection (DPC) during explosive eruptions. The new operational system combines data from low-cost calibrated visible cameras and satellite images to estimate the variation of column height with time and model volcanic plume and fallout in near-real-time(NRT). The new system has three main objectives: (i) to determine column height in NRT using multiple sensors (calibrated cameras and satellite images); (ii) to compute isomass and isopleth maps of tephra deposits in NRT; (iii) to help the DPC to best select the eruption scenarios run daily by INGV-OE every three hours. A particular novel feature of the new system is the computation of an isopleth map, which helps to identify the region of sedimentation of large clasts (≥5 cm) that could cause injuries to tourists, hikers, guides, and scientists, as well as damage buildings in the proximity of the summit craters. The proposed system could be easily adapted to other volcano observatories worldwide.Publishedid 29876V. Pericolosità vulcanica e contributi alla stima del rischioJCR Journa

A new way to reduce the impact from tephra fallout during Etna explosive eruptions

The frequent number of explosive events at Mt. Etna, in Italy, over the last ten years, has made necessary the improvement of volcanic ash monitoring and forecasting system at the Istituto Nazionale di Geofisica e Vulcanologia, Osservatorio Etneo (INGV-OE). Tephra fallout produced during Etna lava fountains largely impact the population living on the volcano flanks. In addition, during one of the most powerful paroxysms, large clasts fell in proximal areas injured tourists and hikers. To reduce risk, the Italian Department Civil Protection (DPC) asked and funded INGV-OE to do a research project finalized to three specific objectives. First, identify the plume scenario (i.e. weak plume scenario (WPS) and strong plume scenarios (SPS)) based on 1-D plume model. Second, forecast characteristics of tephra deposition using near real time observations. Third, identify the region possibly impacted by large clasts (>5 cm). Two algorithms were developed to measure the column height. One from the calibrated images of two visible cameras installed on the S and W flanks of the volcano, respectively; and the other one from satellite data using a procedure based on the computation of the volcanic plume-top brightness temperature at 10.8 mm. The analysis of lava fountains that occurred between 2011 and 2015 provided the opportunity to differentiate between weak, transitional and strong plumes. The uncertainty associated with eruption source parameters, while maintaining a fixed plume height, was also assessed. In the near future the implementation of these products into the INGV-OE - monitoring room will guarantee a better and timely information to civil protection authorities charged of risk prevention at different levels of responsibility.PublishedNapoli6V. Pericolosità vulcanica e contributi alla stima del rischi

Helicobacter pylori, liver cirrhosis, and portal hypertension: an updated appraisal

Helicobacter pylori (H. pylori) is the most common cause of gastritis and peptic ulcer. However, H. pylori is even involved in extragastric diseases, and it has been hypothesized that H. pylori could be a risk factor for several hepatic diseases. For instance, a direct involvement of H. pylori in the development of portal hypertension (PH) in cirrhotic patients has been postulated

Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience

Background: Immune checkpoint inhibitors (ICIs) have widened the therapeutic scenario of different solid tumors over the last ten years. Gastrointestinal (GI) adverse events (AEs), such as diarrhea and colitis, occur in up to 50% of patients treated with ICIs. Materials and methods: We conducted a single-center retrospective analysis in patients with solid tumors treated with ICIs in a 6-year period, from 2015 to 2021, developing GI AEs, for which an endoscopic analysis was performed, with available histological specimens or surgery. Results: Twenty-one patients developed GI AEs under ICIs. The median time from the start of ICIs to the onset of GI AEs was 5 months. Diarrhea was the most frequent symptom (57.2%), upper GI symptoms presented in four patients (19%), while three patients (14.3%) had no symptoms and were diagnosed occasionally. Two patients underwent surgical resection for acute abdomen. Histological findings observed in endoscopic sampling were eosinophilic-pattern gastro-enterocolitis, apoptotic damage, IBD-like features, and ischemic-like changes. Histological damage was also documented in patients with unremarkable endoscopy. Conclusions: Under ICI therapy, GI toxicity is an expected event. Since GIAEs can mimic a broad range of primary GI diseases, a multidisciplinary approach is advocated with upper and lower GI mucosal sampling to remodel therapy and avoid complications

A spinal cord neuroprosthesis for locomotor deficits due to Parkinson’s disease

International audiencePeople with late-stage Parkinson’s disease (PD) often suffer from debilitating locomotor deficits that are resistant to currently available therapies. To alleviate these deficits, we developed a neuroprosthesis operating in closed loop that targets the dorsal root entry zones innervating lumbosacral segments to reproduce the natural spatiotemporal activation of the lumbosacral spinal cord during walking. We first developed this neuroprosthesis in a non-human primate model that replicates locomotor deficits due to PD. This neuroprosthesis not only alleviated locomotor deficits but also restored skilled walking in this model. We then implanted the neuroprosthesis in a 62-year-old male with a 30-year history of PD who presented with severe gait impairments and frequent falls that were medically refractory to currently available therapies. We found that the neuroprosthesis interacted synergistically with deep brain stimulation of the subthalamic nucleus and dopaminergic replacement therapies to alleviate asymmetry and promote longer steps, improve balance and reduce freezing of gait. This neuroprosthesis opens new perspectives to reduce the severity of locomotor deficits in people with PD

Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study

Background Older age and comorbidities are the main risk factors for adverse COVID-19 outcomes in patients with inflammatory bowel disease (IBD). The impact of IBD medications is still under investigation. Aims To assess risk factors for adverse outcomes of COVID-19 in IBD patients and use the identified risk factors to build risk indices. Methods Observational cohort study. Univariable and multivariable logistic regression was used to identify risk factors associated with pneumonia, hospitalisation, need for ventilatory support, and death. Results Of the 937 patients (446 with ulcerative colitis [UC]) evaluated, 128 (13.7%) had asymptomatic SARS-CoV-2 infection, 664 (70.8%) had a favourable course, and 135 (15.5%) had moderate or severe COVID-19. In UC patients, obesity, active disease and comorbidities were significantly associated with adverse outcomes. In patients with Crohn's disease (CD), age, obesity, comorbidities and an additional immune-mediated inflammatory disease were identified as risk factors. These risk factors were incorporated into two indices to identify patients with UC or CD with a higher risk of adverse COVID-19 outcomes. In multivariable analyses, no single IBD medication was associated with poor COVID-19 outcomes, but anti-TNF agents were associated with a lower risk of pneumonia in UC, and lower risks of hospitalisation and severe COVID-19 in CD. Conclusion The course of COVID-19 in patients with IBD is similar to that in the general population. IBD patients with active disease and comorbidities are at greater risk of adverse COVID-19 outcomes. IBD medications do not pose additional risks. The risk indices may help to identify patients who should be prioritised for COVID-19 re-vaccination or for therapies for SARS-CoV-2 infection